The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin

Cooper, 1986, Pharmacokinetics of vancomycin, Vancomycin: a comprehensive review of 30 years clinical experience, 23

Matzke, 1986, Clinical pharmacokinetics of vancomycin, Clin Pharmacokinet, 11, 257, 10.2165/00003088-198611040-00001

Matzke, 1984, Pharmacokinetics of vancomycin in patients with various degrees of renal function, Antimicrob Agents Chemother, 25, 433, 10.1128/AAC.25.4.433

Rodvold, 1988, Vancomycin pharmacokinetics in patients with various degrees of renal function, Antimicrob Agents Chemother, 32, 848, 10.1128/AAC.32.6.848

Rotschafer, 1982, Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations, Antimicrob Agents Chemother, 22, 391, 10.1128/AAC.22.3.391

Blouin, 1982, Vancomycin pharmacokinetics in normal and morbidly obese subjects, Antimicrob Agents Chemother, 21, 575, 10.1128/AAC.21.4.575

Golper, 1988, Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects, Clin Pharmacol Ther, 43, 565, 10.1038/clpt.1988.74

Ackerman, 1988, Vancomycin serum protein binding determination by ultrafiltration, Drug Intell Clin Pharm, 22, 300, 10.1177/106002808802200404

Bailey, 1991, Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin, Antimicrob Agents Chemother, 35, 1089, 10.1128/AAC.35.6.1089

Zokufa, 1989, The influence of serum albumin and alpha 1-acid glycoprotein on vancomycin protein binding in patients with burn injuries, J Burn Care Rehabil, 10, 425, 10.1097/00004630-198909000-00010

Albrecht, 1991, Vancomycin protein binding in patients with infections caused by Staphylococcus aureus, DICP, 25, 713, 10.1177/106002809102500701

Albanese, 2000, Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit, Antimicrob Agents Chemother, 44, 1356, 10.1128/AAC.44.5.1356-1358.2000

Cruciani, 1996, Penetration of vancomycin into human lung tissue, J Antimicrob Chemother, 38, 865, 10.1093/jac/38.5.865

Rodvold, 2004, Plasma and intrapulmonary concentrations of oritavancin and vancomycin in normal healthy adults [abstract O254], Program and abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases (Prague), 44

Lamer, 1993, Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients, Antimicrob Agents Chemother, 37, 281, 10.1128/AAC.37.2.281

Craig, 2004, Activity of oritavancin versus vancomycin in the neutropenic murine thigh-and lung-infection models [abstract A-1863], Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC), 37

LaPlante, 2004, Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model, Antimicrob Agents Chemother, 48, 4665, 10.1128/AAC.48.12.4665-4672.2004

Stanley, 1994, Effect of human serum on killing activity of vancomycin and teicoplanin against Staphylococcus aureus, Pharmacotherapy, 14, 35, 10.1002/j.1875-9114.1994.tb02786.x

Lamp, 1992, In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin, Antimicrob Agents Chemother, 36, 2709, 10.1128/AAC.36.12.2709

Ross, 2002, Glycopeptide pharmacodynamics. In: Nightingale CH, Murakawa T, Ambrose PG, eds. Antimicrobial pharmacodynamics in theory and clinical practice. 1st ed, New York: Marcel Dekker, 177

Larsson, 1996, The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions, J Antimicrob Chemother, 38, 589, 10.1093/jac/38.4.589

Lowdin, 1998, In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis, Antimicrob Agents Chemother, 42, 2739, 10.1128/AAC.42.10.2739

Ebert, In vivo cidal activity and pharmacokinetic parameters for vancomycin against methicillin-susceptible and -resistant S. aureus [abstract 439]. In: Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy (New York), 1987

Knudsen, 1997, Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model, Antimicrob Agents Chemother, 41, 1910, 10.1128/AAC.41.9.1910

Rybak, 1997, Influence of vancomycin serum concentrations on the outcome of patients being treated for gram-positive infections [abstract A-46], Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto), 9

Moise-Broder, 2004, Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections, Clin Pharmacokinet, 43, 925, 10.2165/00003088-200443130-00005

Drew, 2004, Lack of relationship between predicted area under the time-concentration curve/minimum inhibitory concentration and outcome in vancomycin-treated patients with Staphylococcus aureus bacteremia [abstract A-1493], Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC), 36

Rybak, 2001, Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options, Drugs, 61, 1, 10.2165/00003495-200161010-00001

Fridkin, 2001, Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know, Clin Infect Dis, 32, 108, 10.1086/317542

Carey, 2004, Failure of automated systems to detect vancomycin-resistant Staphylococcus aureus [abstract D-66], Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC), 142

Moore, 2003, Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis, Antimicrob Agents Chemother, 47, 1262, 10.1128/AAC.47.4.1262-1266.2003

Howden, 2004, Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility, Clin Infect Dis, 38, 521, 10.1086/381202

Liu, 2003, Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods, Antimicrob Agents Chemother, 47, 3040, 10.1128/AAC.47.10.3040-3045.2003

Charles, 2004, Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus, Clin Infect Dis, 38, 448, 10.1086/381093

Wood, 1986, Vancomycin enhancement of experimental tobramycin nephrotoxicity, Antimicrob Agents Chemother, 30, 20, 10.1128/AAC.30.1.20

Wold, 1981, Toxicology of vancomycin in laboratory animals, Rev Infect Dis, 3, 224, 10.1093/clinids/3.Supplement.S224

Rybak, 1990, Nephrotoxicity of vancomycin, alone and with an aminoglycoside, J Antimicrob Chemother, 25, 679, 10.1093/jac/25.4.679

Cimino, 1987, Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy, Am J Med, 83, 1091, 10.1016/0002-9343(87)90947-8

Farber, 1983, Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981, Antimicrob Agents Chemother, 23, 138, 10.1128/AAC.23.1.138

Pestotnik, 1997, Adverse effects of intravenous vancomycin in hospitalized patients: attributable costs and excess length of stay [abstract 376], Program and abstracts of the 35th Annual Meeting of the Infectious Diseases Society of America (San Francisco), 424

Sorrell, 1985, A prospective study of adverse reactions associated with vancomycin therapy, J Antimicrob Chemother, 16, 235, 10.1093/jac/16.2.235

Elting, 1998, Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice, Cancer, 83, 2597, 10.1002/(SICI)1097-0142(19981215)83:12<2597::AID-CNCR27>3.0.CO;2-L

Tange, 1989, An experimental study of vancomycin-induced cochlear damage, Arch Otorhinolaryngol, 246, 67, 10.1007/BF00457456

Brummett, 1989, Vancomycin- and erythromycin-induced hearing loss in humans, Antimicrob Agents Chemother, 33, 791, 10.1128/AAC.33.6.791

Cantu, 1990, Protein binding of vancomycin in a patient with immunoglobulin A myeloma, Antimicrob Agents Chemother, 34, 1459, 10.1128/AAC.34.7.1459

Lundstrom, 1995, Vancomycin, trimethoprim-sulfamethoxazole, and rifampin, Infect Dis Clin North Am, 9, 747, 10.1016/S0891-5520(20)30695-4

Lundstrom, 2004, Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin, Infect Dis Clin North Am, 18, 651, 10.1016/j.idc.2004.04.014

American Thoracic Society, 2005, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia, Am J Respir Crit Care Med, 171, 388, 10.1164/rccm.200405-644ST